| Drug Name |
Zileuton |
| Drug ID |
BADD_D02384 |
| Description |
Leukotrienes are substances that induce numerous biological effects including augmentation of neutrophil and eosinophil migration, neutrophil and monocyte aggregation, leukocyte adhesion, increased capillary permeability, and smooth muscle contraction. These effects contribute to inflammation, edema, mucus secretion, and bronchoconstriction in the airways of asthmatic patients. Zileuton relieves such symptoms through its selective inhibition of 5-lipoxygenase, the enzyme that catalyzes the formation of leukotrienes from arachidonic acid. Specifically, it inhibits leukotriene LTB4, LTC4, LTD4, and LTE4 formation. Both the R(+) and S(-) enantiomers are pharmacologically active as 5-lipoxygenase inhibitors in in vitro systems. The immediate release tablet of Zileuton has been withdrawn from the US market. |
| Indications and Usage |
For the prophylaxis and chronic treatment of asthma in adults and children 12 years of age and older. |
| Marketing Status |
approved; investigational; withdrawn |
| ATC Code |
Not Available |
| DrugBank ID |
DB00744
|
| KEGG ID |
D00414
|
| MeSH ID |
C063449
|
| PubChem ID |
60490
|
| TTD Drug ID |
D09JUG
|
| NDC Product Code |
10122-901; 50384-5000; 76055-0002; 64980-206; 49706-2115; 59285-035; 72643-022; 64380-189; 42973-156; 14501-0056; 49884-723; 51407-741; 31722-044; 69339-130; 13672-010 |
| UNII |
V1L22WVE2S
|
| Synonyms |
zileuton | N-(1-benzo(b)thien-2-ylethyl)-N-hydroxyurea | A 64077 | Abbot 64077 | A-64077 | Zyflo |
